Omkar Speciality Chemicals Ltd
Incorporated in 1993, Omkar Specialty Chemicals Ltd is a global specialty chemicals company.[1]
- Market Cap ₹ 7.02 Cr.
- Current Price ₹ 3.41
- High / Low ₹ 6.40 / 3.35
- Stock P/E
- Book Value ₹ 9.09
- Dividend Yield 0.00 %
- ROCE %
- ROE -8.49 %
- Face Value ₹ 10.0
Pros
- Stock is trading at 0.38 times its book value
- Promoter holding has increased by 90.1% over last quarter.
Cons
- Company has low interest coverage ratio.
- The company has delivered a poor sales growth of -81.4% over past five years.
- Working capital days have increased from -10,77,662 days to 2,39,805 days
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Commodities Chemicals Chemicals & Petrochemicals Specialty Chemicals
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 193.32 | 319.06 | 316.74 | 197.64 | 42.65 | 56.61 | 44.97 | 22.98 | 7.02 | 0.06 | 0.00 | 0.01 | 0.09 | |
| 164.38 | 273.64 | 359.84 | 241.00 | 43.95 | 56.86 | 37.59 | 28.69 | 9.64 | 1.11 | 0.62 | 0.87 | 0.81 | |
| Operating Profit | 28.94 | 45.42 | -43.10 | -43.36 | -1.30 | -0.25 | 7.38 | -5.71 | -2.62 | -1.05 | -0.62 | -0.86 | -0.72 |
| OPM % | 14.97% | 14.24% | -13.61% | -21.94% | -3.05% | -0.44% | 16.41% | -24.85% | -37.32% | -1,750.00% | -8,600.00% | -800.00% | |
| 4.91 | 8.75 | -60.96 | -48.90 | 12.39 | 0.45 | 4.90 | 0.96 | -145.85 | 0.09 | 0.22 | 0.16 | 0.08 | |
| Interest | 11.43 | 16.52 | 21.83 | 26.13 | 14.62 | 4.93 | 5.57 | 6.07 | 32.50 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation | 1.97 | 4.28 | 10.90 | 8.16 | 7.99 | 6.59 | 3.56 | 1.79 | 1.08 | 1.01 | 0.91 | 0.89 | 0.90 |
| Profit before tax | 20.45 | 33.37 | -136.79 | -126.55 | -11.52 | -11.32 | 3.15 | -12.61 | -182.05 | -1.97 | -1.31 | -1.59 | -1.54 |
| Tax % | 12.27% | 33.44% | -20.05% | -17.84% | 46.44% | 29.33% | 36.19% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | |
| 17.93 | 22.21 | -109.36 | -103.97 | -16.87 | -14.63 | 2.01 | -12.61 | -182.04 | -1.97 | -1.30 | -1.59 | -1.54 | |
| EPS in Rs | 8.70 | 10.78 | -53.09 | -50.47 | -8.19 | -7.10 | 0.98 | -6.12 | -88.37 | -0.96 | -0.63 | -0.77 | -0.74 |
| Dividend Payout % | 17.22% | 13.90% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | -65% |
| 5 Years: | -81% |
| 3 Years: | -89% |
| TTM: | % |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | -25% |
| 3 Years: | 25% |
| TTM: | -11% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | -27% |
| 5 Years: | -28% |
| 3 Years: | -27% |
| 1 Year: | -42% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| Last Year: | -8% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 20.58 | 20.58 | 20.58 | 20.58 | 20.58 | 20.58 | 20.58 | 20.58 | 20.58 | 20.58 | 20.58 | |
| Reserves | 142.37 | 160.87 | -23.39 | -145.66 | -168.66 | -183.07 | -178.91 | -191.63 | -373.81 | -375.78 | -1.85 | |
| 175.51 | 185.76 | 180.65 | 232.71 | 229.50 | 233.31 | 228.09 | 225.51 | 382.36 | 382.35 | 3.11 | ||
| 50.13 | 79.52 | 135.49 | 28.48 | 25.77 | 26.45 | 16.61 | 17.71 | 17.24 | 22.08 | 23.81 | ||
| Total Liabilities | 388.59 | 446.73 | 313.33 | 136.11 | 107.19 | 97.27 | 86.37 | 72.17 | 46.37 | 49.23 | 45.65 | |
| 68.30 | 77.90 | 168.47 | 76.29 | 68.43 | 53.14 | 27.91 | 26.12 | 21.88 | 20.86 | 19.07 | ||
| CWIP | 107.35 | 112.67 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.20 | |
| Investments | 13.80 | 13.91 | 0.14 | 10.92 | 0.35 | 0.38 | 0.71 | 0.43 | 0.07 | 0.07 | 0.07 | |
| 199.14 | 242.25 | 144.72 | 48.90 | 38.41 | 43.75 | 57.75 | 45.62 | 24.42 | 28.30 | 26.31 | ||
| Total Assets | 388.59 | 446.73 | 313.33 | 136.11 | 107.19 | 97.27 | 86.37 | 72.17 | 46.37 | 49.23 | 45.65 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 52.85 | -9.40 | 107.30 | 25.96 | 1.38 | 4.02 | -16.41 | 0.89 | -124.18 | 0.20 | 0.91 | -1.60 | |
| -76.06 | 11.71 | -119.90 | -64.33 | 10.90 | 1.51 | 17.35 | 0.17 | 0.29 | -0.17 | 0.11 | -0.13 | |
| 17.33 | -7.91 | 15.75 | 35.24 | -13.55 | -5.30 | -1.08 | -1.04 | 124.40 | 0.00 | 0.00 | -0.05 | |
| Net Cash Flow | -5.88 | -5.59 | 3.16 | -3.13 | -1.28 | 0.23 | -0.14 | 0.03 | 0.50 | 0.03 | 1.02 | -1.78 |
| Free Cash Flow | -13.54 | -28.61 | 46.77 | -28.42 | 1.26 | 5.52 | 0.82 | 0.89 | -121.02 | 0.13 | 0.91 | -1.80 |
| CFO/OP | 187% | -26% | -233% | -61% | -106% | -1,608% | -222% | -16% | 4,740% | -19% | -147% | 186% |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 128.58 | 116.98 | 90.10 | 19.02 | 74.37 | 30.05 | 111.44 | 32.56 | 9.36 | 0.00 | 0.00 | |
| Inventory Days | 148.58 | 99.08 | 109.64 | 7.51 | 37.27 | 31.46 | 17.96 | 39.78 | 7.28 | 60.83 | 365.00 | |
| Days Payable | 96.33 | 81.02 | 138.60 | 31.59 | 259.10 | 147.68 | 139.44 | 215.28 | 902.94 | 63,510.00 | 0.00 | |
| Cash Conversion Cycle | 180.82 | 135.04 | 61.14 | -5.05 | -147.46 | -86.17 | -10.05 | -142.95 | -886.30 | -63,449.17 | 365.00 | |
| Working Capital Days | -89.12 | 38.30 | 9.86 | -295.95 | -1,360.98 | -1,002.15 | -1,064.56 | -3,296.44 | -20,208.11 | -2,395,130.00 | 239,805.00 | |
| ROCE % | 10.11% | 14.14% | -18.99% | -34.48% | -8.32% | -8.47% | 6.66% | -10.53% | -8.42% | -7.00% |
Insights
In beta| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | |
|---|---|---|---|---|---|---|---|---|
| Installed Volumetric Capacity tonnes per annum (TPA) |
|
|||||||
| Export Revenue Share % of total revenue |
||||||||
| Number of Manufacturing Units count |
||||||||
| Number of Process Patents count |
||||||||
| Production Volume tonnes per annum (TPA) |
||||||||
| Capacity Utilization (Overall) % of rated capacity |
||||||||
| Number of Countries Exported To count |
||||||||
| Number of Products count |
||||||||
Extracted by Screener AI
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
- Submission of newspaper publication of unaudited financial results for quarter result ended 30 June 2026
-
Board Meeting Outcome for Outcome Of The Board Meeting Held On Friday, August 14, 2026
- Board approved Q1 FY2026-27 unaudited results; loss Rs.36.07 lakh, no revenue, resolution plan implemented.
-
Board Meeting Intimation for Intimation Of Board Meeting Scheduled To Be Held On 14Th August, 2026
- Board meeting on 14 August 2026 to consider Q1 FY2026-27 unaudited financial results.
- Announcement under Regulation 30 (LODR)-Newspaper Publication
- Announcement under Regulation 30 (LODR)-Newspaper Publication
Annual reports
-
Annual Report 2021
from bse
-
Annual Report 2020
from bse
-
Annual Report 2019
from bse
-
Annual Report 2018
from bse
-
Annual Report 2017
from bse
-
Annual Report 2016
from bse
-
Annual Report 2015
from bse
-
Annual Report 2014
from bse
-
Annual Report 2013
from nse
-
Annual Report 2013
from bse
-
Annual Report 2012
from bse
-
Annual Report 2011
from bse
Concalls
-
Aug 2017Transcript
-
May 2017Transcript
-
May 2017Transcript
-
Nov 2016Transcript
-
Nov 2016Transcript
-
Aug 2016Transcript
-
Aug 2016Transcript
-
Jun 2016Transcript PPT
-
Apr 2016Transcript
-
Feb 2016Transcript
-
Dec 2015PPT
Business Overview:[1][2]
a) OSCL manufactures specialty chemicals and pharma intermediates like organic and inorganic chemicals, and organo-inorganic intermediates.
b) The Inorganic Intermediates include Molybdenum derivatives, Selenium derivatives, Iodine derivatives, Cobalt derivatives, Bismuth & Tungsten derivatives, and organic intermediates include Tartaric acid derivatives and other intermediates.
c) The pharmaceutical industry remains the major end user segment of the company, accounting for nearly 70-75% of its revenues, with poultry, glass, and water treatment being the other major end user segments.